{"id":"W1982688102","doi":"10.1038/sj.gt.3302802","title":"Angiogenic gene therapy in patients with nonrevascularizable ischemic heart disease: a phase 2 randomized, controlled trial of AdVEGF121 (AdVEGF121) versus maximum medical treatment","year":2006,"lang":"en","type":"article","venue":"Gene Therapy","topic":"Angiogenesis and VEGF in Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":283,"is_retracted":false,"has_abstract":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Manitoba Health; Hôpital du Sacré-Cœur de Montréal; Vancouver Hospital and Health Sciences Centre; St. Michael's Hospital; Sunnybrook Health Science Centre; Victoria Heart Institute Foundation; University of Alberta Hospital; Montreal Heart Institute; Alberta Hospital Edmonton; Foothills Medical Centre; Royal Victoria Hospital; Women's College Hospital; Hôpital Notre-Dame; London Health Sciences Centre","funders":"","keywords":"Angina; Medicine; Revascularization; Genetic enhancement; Canadian Cardiovascular Society; Clinical endpoint; Coronary artery disease; Cardiology; Randomized controlled trial; Internal medicine; Therapeutic angiogenesis; Perfusion; Adverse effect; Surgery; Angiogenesis; Neovascularization; Myocardial infarction; Gene; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005599066,0.0004256441,0.001215663,0.00009889588,0.0000659677,0.00001699239,0.0002378212,0.0002262013,0.0001976431],"category_scores_gemma":[0.00003484896,0.0002812724,0.0009266749,0.0001748055,0.000191059,0.000008135518,0.00003065013,0.00006191257,0.000004300266],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00006010406,"about_ca_system_score_gemma":0.0004266557,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001610577,"about_ca_topic_score_gemma":0.00002671749,"domain_scores_codex":[0.9973822,0.000338711,0.0007054538,0.0005752943,0.0005545103,0.0004437984],"domain_scores_gemma":[0.9987413,0.0000712635,0.0002563107,0.0006143826,0.0001438852,0.0001728864],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9408261,0.002914419,0.00154737,0.000004791872,0.001022895,0.000006592223,0.00001756775,0.0001063417,0.04950174,0.000004661375,0.0002972283,0.003750337],"study_design_scores_gemma":[0.9093948,0.004159005,0.0004492999,0.00001524367,0.0001272439,0.000001320405,0.000003914894,0.00004281674,0.07986363,0.00002088744,0.005607,0.0003148529],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.968252,0.02737656,0.0003734077,0.0001429189,0.0002654624,0.003391456,0.00006393236,0.00001483552,0.0001194214],"genre_scores_gemma":[0.9881224,0.008477384,0.0003684329,0.0002407691,0.0006055271,0.001200762,0.0006826682,0.00006871061,0.0002333586],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.03143128,"threshold_uncertainty_score":0.9999639,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.008016024261516347,"score_gpt":0.2603112171652076,"score_spread":0.2522951929036913,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}